COGT Cogent Biosciences
- 7.530
- +0.240+3.29%
- 7.500
- -0.030-0.40%
Cogent Biosciences News
Cogent Biosciences: A Strong Buy on Oncology Asset Potential and Favorable Market Dynamics
Cogent Announces IPv4 Address Securitization Offering
WASHINGTON, April 25, 2024 /PRNewswire/ -- Cogent Communications Holdings, Inc. (NASDAQ: CCOI) (the "Company" or "Cogent") yesterday announced that a special-purpose, bankruptcy remote, indirect whol
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) fell sharply in today's pre-market trading a
Express News | Cogent Biosciences Reported Preclinical Data From CNS-Penetrant ErbB2 Inhibitor Program
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
COGT Reports Full Year 2023 Financial Results and Business Highlights
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Celldex (CLDX) and Laboratory (LH)
Cogent Biosciences Is Maintained at Overweight by JP Morgan
Cogent Biosciences Is Maintained at Overweight by JP Morgan
Express News | JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $20
Analysts Offer Insights on Healthcare Companies: Cigna (CI), Cogent Biosciences (COGT) and Canopy Growth (CGC)
Cogent Biosciences Is Maintained at Buy by Citigroup
Cogent Biosciences Is Maintained at Buy by Citigroup
Express News | Citigroup Maintains Buy on Cogent Biosciences, Raises Price Target to $13
Cogent Downgraded at Baird on Rare Disease Drug Data
Express News | Cogent Biosciences Q4 EPS $(0.63) Down From $(0.56) YoY
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersZyVersa Therapeutics (NASDAQ:ZVSA) stock increased by 44.8% to $1.16 during Monday's pre-market session. The market value of their outstanding shares is at $5.3 million. Agiliti (NYSE:AGTI) sha
Cogent Biosciences Had Cash, Cash Equivalents and Marketable Securities of $273.2M at Dec 31
Cogent Biosciences Had Cash, Cash Equivalents and Marketable Securities of $273.2M at Dec 31
Cogent Biosciences 4Q Loss $54.4M >COGT
Cogent Biosciences 4Q Loss $54.4M >COGT
Press Release: Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results -- UMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initi
Cogent Biosciences Price Target Cut to $8.00/Share From $14.00 by Baird
Cogent Biosciences Price Target Cut to $8.00/Share From $14.00 by Baird
Cogent Biosciences Cut to Neutral From Outperform by Baird
Cogent Biosciences Cut to Neutral From Outperform by Baird
Analysis
Price Target
No Data
